JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 243 filers reported holding JUNO THERAPEUTICS INC in Q4 2017. The put-call ratio across all filers is 0.72 and the average weighting 0.8%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2017 | $2,081,000 | +5376.3% | 45,532 | +4448.7% | 0.21% | +1530.8% |
Q2 2016 | $38,000 | -60.0% | 1,001 | -60.0% | 0.01% | -67.5% |
Q1 2016 | $95,000 | +13.1% | 2,501 | +31.6% | 0.04% | -29.8% |
Q4 2015 | $84,000 | – | 1,901 | +190000.0% | 0.06% | – |
Q3 2015 | $0 | -100.0% | 1 | -100.0% | 0.00% | -100.0% |
Q2 2015 | $121,000 | +3933.3% | 2,268 | +4436.0% | 0.14% | +2760.0% |
Q1 2015 | $3,000 | – | 50 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Biomark Capital Management Co. LLC | 2,168,601 | $65,080,000 | 86.12% |
Crestline Management, LP | 17,348,799 | $520,637,000 | 66.02% |
Omega Fund Management, LLC | 1,229,512 | $36,898,000 | 28.17% |
SIB LLC | 100,000 | $3,001,000 | 2.42% |
Clarius Group, LLC | 117,896 | $3,538,000 | 1.65% |
BB BIOTECH AG | 1,405,000 | $42,164,000 | 1.48% |
Duquesne Family Office | 493,000 | $14,795,000 | 1.31% |
First Washington CORP | 65,320 | $1,960,000 | 1.10% |
PFM Health Sciences, LP | 1,124,285 | $33,740,000 | 0.99% |
Partner Investment Management, L.P. | 18,376 | $551,000 | 0.82% |